Type 1 diabetes

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for anti-CD3-directed antibody TZIELD (teplizumab-mzwv), the first immunomodulatory treatment for type 1 diabetes (T1D).   It is approved for intravenous use to delay the onset of stage 3 T1D in adult and paediatric patients aged eight years and older with stage 2 […]

For World Diabetes Day, DDW’s Diana Spencer provides an overview of the latest innovations in the treatment of the disease. Here are 2022’s five most significant discoveries (in no particular order):  1. Human beta cell model Earlier this year, Human Cell Design, a biotechnology company focused on generating translational human cellular models, launched Endoc-BH5 to […]